(WO201773910) The present invention relates to a method for direct transdifferentiation into neurons using metal nanoparticles magnetized from an electromagnetic field, and to a cell therapeutic agent for the treatment of cerebral nerve diseases, comprising neurons differentiated by the method. In the present invention, it was specifically verified that the direct transdifferentiation efficiency into neurons can be remarkably improved through the above method and the symptoms of cerebral nerve diseases, such as a stroke, can be effectively alleviated. Therefore, in the treatment of degenerative cerebral nerve diseases, the target therapy is expected to be implemented through a more fundamental approach.
(WO201744853) In some embodiments, the present invention provides methods including the steps of providing one or more human somatic cells, causing transient increased expression of OCT4, KLF4, SOX2, and cMYC in the somatic cells forming modified somatic cells, providing a plurality of inactivated embryonic fibroblasts, associating the modified somatic cells with the inactivated embryonic fibroblasts in a culture media comprising 20% KO DMEM xeno-free serum replacement and at least 15 ng/ml recombinant bFGF to form human induced neural stem cells.
(WO201744811) The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein having specific glycosylation patterns. The present disclosure relates to, inter alia, a recombinant eculizumab protein or a recombinant eculizumab variant protein made from CHO cells. The present disclosure also relates to methods for the use of these proteins.
(WO201744776) The present invention includes a modified single-guide RNA (sgRNA) template with improved knockout efficiency specific for a target gene comprising an sgRNA construct comprising at least one of a mutated duplex region wherein a length of the duplex region is extended, or a mutated poly T region at the beginning of the duplex region, wherein the sgRNA has a greater target gene knockout efficiency in cells.
(WO201744780) The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.
(WO201744773) The present invention relates to transgenic citrus trees resistant to Huanglongbing disease (HLB) through overexpression of AtNPR1 either in the phloem tissues (where HLB resides) via utilization of a phloem specific Arabidopsis sucrose-proton symporter 2 (AtSUC2) promoter or a constitutive CaMV 35S promoter for HLB resistance. Evaluation of these transgenic plants demonstrates that overexpressing the AtNPR1 can result in effective HLB resistance in citrus.
(WO201744768) Provided herein are RNA triple helix structures. The RNA triple helix may be associated with a dendrimer to form an RNA triple helix-dendrimer conjugate, which may be applied to a biological tissue, such as a tumor. The RNA triple helix-dendrimer conjugate may be disposed in a hydrogel. The hydrogel may be applied to a biological tissue, such as a tumor. The hydrogel and/or dendrimer may control the release of the RNA triple helix. Methods of treating a biological tissue and kits also are provided.